MCID: RNL015
MIFTS: 47

Renal Hypertension

Categories: Cardiovascular diseases, Ear diseases, Genetic diseases, Nephrological diseases, Rare diseases

Aliases & Classifications for Renal Hypertension

MalaCards integrated aliases for Renal Hypertension:

Name: Renal Hypertension 12 74 15 17 71
Hypertension, Renal 43
Hypertension Renal 54

Classifications:



External Ids:

Disease Ontology 12 DOID:1073
MeSH 43 D006977
NCIt 49 C3121
SNOMED-CT 67 28119000
UMLS 71 C0020544

Summaries for Renal Hypertension

MalaCards based summary : Renal Hypertension, also known as hypertension, renal, is related to chronic pyelonephritis and hypertensive nephropathy. An important gene associated with Renal Hypertension is EDN1 (Endothelin 1), and among its related pathways/superpathways are Pathways in cancer and Development Angiotensin activation of ERK. The drugs Hydrochlorothiazide and Indapamide have been mentioned in the context of this disorder. Affiliated tissues include kidney, heart and testes, and related phenotypes are cardiovascular system and homeostasis/metabolism

Wikipedia : 74 Renovascular hypertension is a condition in which high blood pressure is caused by the kidneys' hormonal... more...

Related Diseases for Renal Hypertension

Diseases in the Renal Hypertension family:

Renal Failure, Progressive, with Hypertension

Diseases related to Renal Hypertension via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 326)
# Related Disease Score Top Affiliating Genes
1 chronic pyelonephritis 30.8 REN ALB ACE
2 hypertensive nephropathy 30.8 ALB AGTR1 ACE
3 familial hypertension 30.6 REN AGTR1 AGT
4 uremia 30.5 REN EPO ALB ACE
5 hypertension, diastolic 30.5 REN ACE
6 acute kidney failure 30.5 REN KNG1 ALB
7 pure autonomic failure 30.4 REN EPO DBH ACE
8 fibromuscular dysplasia 30.4 REN AGTR1 AGT ACE
9 renovascular hypertension 30.4 REN NPPB NOS3 KNG1 EDN1 AGTR1
10 renal fibrosis 30.4 REN MIR200B ALB AGTR1 AGT
11 glomerulonephritis 30.3 MYH9 APOL1 ALB AGTR1 ACE
12 cystic kidney disease 30.3 REN EPO ALB ACE
13 atherosclerosis susceptibility 30.3 NOS3 EDN1 ALB AGTR1 ACE
14 hepatorenal syndrome 30.3 REN EDN1 ALB ACE
15 hypertensive retinopathy 30.2 REN ALB AGTR1 ACE
16 malignant hypertension 30.2 REN NPPB EDN1 AGTR1 AGT ADM
17 microvascular complications of diabetes 3 30.2 REN ALB AGTR1 ACE
18 kidney hypertrophy 30.2 REN ALB ACE
19 malignant renovascular hypertension 30.1 REN EDN1 AGTR1
20 coronary stenosis 30.1 NPPB ALB ACE
21 portal hypertension 30.1 NOS3 EDN1 ALB AGTR1 ACE
22 liver cirrhosis 30.0 REN KLKB1 EDN1 ALB ADM
23 hypokalemia 30.0 SLC12A3 REN ALB ACE
24 gitelman syndrome 30.0 SLC12A3 REN AGT
25 pheochromocytoma 30.0 REN KNG1 EPO EDN1 DBH ADM
26 urinary tract obstruction 29.9 REN ALB AGTR1 ACE
27 liddle syndrome 1 29.9 SLC12A3 REN AGT
28 hypertensive encephalopathy 29.9 REN NOS3 EPO ALB AGTR1 ACE
29 renal tubular dysgenesis 29.8 REN AGTR1 AGT ACE
30 renal dysplasia 29.8 REN AGTR1 AGT ACE
31 retinal vascular disease 29.8 REN NOS3 EDN1 ALB ACE
32 peripheral vascular disease 29.7 NOS3 KNG1 EPO ALB ACE
33 focal segmental glomerulosclerosis 29.7 MYH9 APOL1 ALB AGTR1 ACE
34 coronary heart disease 1 29.7 NPPB NOS3 EDN1 AGTR1 ACE
35 hypertensive heart disease 29.7 REN NPPB AGTR1 AGT ACE
36 ischemia 29.5 NPPB NOS3 KNG1 EPO EDN1 ACE
37 pulmonary hypertension 29.5 REN NPPB NOS3 EDN1 ALB AGTR1
38 sleep apnea 29.5 REN NPPB NOS3 EPO EDN1 ALB
39 eclampsia 29.5 REN NOS3 EDN1 ALB AGT ACE
40 polycystic kidney disease 29.4 REN NOS3 EPO EDN1 ALB AGTR1
41 diastolic heart failure 29.4 REN NPPB NOS3 AGTR1 AGT ACE
42 vascular disease 29.4 REN NPPB NOS3 KNG1 EPO EDN1
43 pre-eclampsia 29.3 REN NOS3 KNG1 EDN1 ALB AGTR1
44 autosomal dominant polycystic kidney disease 29.2 REN NOS3 EDN1 ALB AGTR1 AGT
45 body mass index quantitative trait locus 11 29.2 REN NOS3 KNG1 EDN1 ALB AGT
46 pulmonary edema 29.1 REN NPPB NOS3 KNG1 EPO EDN1
47 diabetes mellitus 29.0 REN NPPB NOS3 KNG1 EPO EDN1
48 end stage renal disease 29.0 REN NOS3 MYH9 EPO APOL1 ALB
49 chronic kidney disease 28.8 REN NPPB NOS3 MYH9 EPO EDN1
50 kidney disease 28.6 SLC12A3 REN NPPB NOS3 MYH9 MIR200A

Graphical network of the top 20 diseases related to Renal Hypertension:



Diseases related to Renal Hypertension

Symptoms & Phenotypes for Renal Hypertension

MGI Mouse Phenotypes related to Renal Hypertension:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.97 ACE ADM AGT AGTR1 ALB DBH
2 homeostasis/metabolism MP:0005376 9.8 ACE ADM AGT AGTR1 ALB DBH
3 renal/urinary system MP:0005367 9.32 ACE ADM AGT AGTR1 ALB EDN1

Drugs & Therapeutics for Renal Hypertension

Drugs for Renal Hypertension (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 140)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Hydrochlorothiazide Approved, Vet_approved Phase 4 58-93-5 3639
2
Indapamide Approved Phase 4 26807-65-8 3702
3
Angiotensin II Approved, Investigational Phase 4 4474-91-3, 11128-99-7, 68521-88-0 172198
4
Candesartan cilexetil Approved Phase 4 145040-37-5 2540
5
Irbesartan Approved, Investigational Phase 4 138402-11-6 3749
6
Captopril Approved Phase 4 62571-86-2 44093
7
Amlodipine Approved Phase 4 88150-42-9 2162
8
Bisoprolol Approved Phase 4 66722-44-9 2405
9
Candesartan Experimental Phase 4 139481-59-7 2541
10 Sodium Chloride Symporter Inhibitors Phase 4
11 Angiotensin-Converting Enzyme Inhibitors Phase 4
12 Angiotensin Receptor Antagonists Phase 4
13 Angiotensin II Type 1 Receptor Blockers Phase 4
14 Angiotensinogen Phase 4
15 Giapreza Phase 4
16 HIV Protease Inhibitors Phase 4
17
protease inhibitors Phase 4
18 Adrenergic beta-1 Receptor Antagonists Phase 4
19 Adrenergic Agents Phase 4
20 Hormones Phase 4
21 Adrenergic Antagonists Phase 4
22 Vasodilator Agents Phase 4
23 Sympatholytics Phase 4
24 Adrenergic beta-Antagonists Phase 4
25 Neurotransmitter Agents Phase 4
26 Calcium, Dietary Phase 4
27 calcium channel blockers Phase 4
28 Antihypertensive Agents Phase 4
29
Calcium Nutraceutical Phase 4 7440-70-2 271
30
Telmisartan Approved, Investigational Phase 3 144701-48-4 65999
31
Losartan Approved Phase 3 114798-26-4 3961
32
Atenolol Approved Phase 3 29122-68-7 2249
33
Lisinopril Approved, Investigational Phase 3 76547-98-3, 83915-83-7 5362119
34
Diltiazem Approved, Investigational Phase 3 42399-41-7 39186
35
Hydralazine Approved Phase 3 86-54-4 3637
36
Metoprolol Approved, Investigational Phase 3 37350-58-6, 51384-51-1 4171
37
Minoxidil Approved, Investigational Phase 3 38304-91-5 4201
38
Clonidine Approved Phase 3 4205-90-7 2803
39
Sodium citrate Approved, Investigational Phase 3 68-04-2
40
Magnesium citrate Approved Phase 3 3344-18-1
41
Bevacizumab Approved, Investigational Phase 3 216974-75-3
42
Dimenhydrinate Approved Phase 3 523-87-5 441281
43
Bisacodyl Approved Phase 3 603-50-9
44
Chlorothiazide Approved, Vet_approved Phase 3 58-94-6 2720
45
Spironolactone Approved Phase 3 52-01-7, 1952-01-7 5833
46
Mycophenolic acid Approved Phase 3 24280-93-1 446541
47
Tacrolimus Approved, Investigational Phase 3 104987-11-3 445643 439492 6473866
48
tannic acid Approved Phase 3 1401-55-4
49
Benzocaine Approved, Investigational Phase 3 94-09-7, 1994-09-7 2337
50
Citric acid Approved, Nutraceutical, Vet_approved Phase 3 77-92-9 311

Interventional clinical trials:

(show top 50) (show all 143)
# Name Status NCT ID Phase Drugs
1 Renal Sympathetic Denervation in Patients With Mild Refractory Hypertension Completed NCT01656096 Phase 4
2 A Comparison of Indapamide SR 1.5 mg With Hydrochlorothiazide 25 mg, in Combination With an ACE-inhibitor, in Old Patients With Mild to Moderate Renal Insufficiency and Hypertension Completed NCT01172431 Phase 4 Indapamide;Hydrochlorothiazide
3 Effect of Lower Body Negative Pressure and Angiotensin II Receptor Blockade on Renal Hemodynamic, Neuro-hormonal and Tubular Response in Pre-hypertensive States: a Randomized Controlled Trial. Completed NCT01734096 Phase 4 Candesartan cilexetil
4 An Open-label, Randomized, Parallel-group Study to Evaluate the Acute and Steady-state Renal Hemodynamic Responses to Aliskiren in Patients With Type 2 Diabetes Mellitus Completed NCT00660309 Phase 4 Aliskiren;Irbesartan;Captopril
5 Renal Denervation in Patients With Resistant Hypertension Completed NCT01570777 Phase 4
6 Effect of Amlodipine Versus Bisoprolol on Hypertensive Patients With End-stage Renal Disease on Maintenance Hemodialysis. Active, not recruiting NCT04085562 Phase 4 Bisoprolol Fumarate 5-10 mg;Amlodipine 5-10 mg
7 Renal Denervation for Complicated Hypertension (RDNP-2012-03) Terminated NCT01865253 Phase 4
8 Renal Denervation for Resistant Hypertension Terminated NCT01865240 Phase 4
9 DENERVATION OF RENAL SYMPATHETIC ACTIVITY AND HYPERTENSION STUDY Unknown status NCT01522430 Phase 3
10 Sympathetic Renal Denervation in Heart Failure With Normal LV Ejection Fraction: Denervation of the renAl sympathetIc nerveS in hearT Failure With nOrmal Lv Ejection Fraction Unknown status NCT01583881 Phase 2, Phase 3
11 Percutaneous Renal Stenting in Renovascular Disease With or Without Distal Atheroembolic Protection Unknown status NCT00868972 Phase 2, Phase 3
12 A Multi-center, Open Label Study for Evaluation of the Safety, Tolerability and Efficacy of 8-week Treatment With LCZ696 in Japanese Hypertensive Patients With Renal Dysfunction Completed NCT01593787 Phase 3 LCZ696
13 Renal Sympathetic Denervation as a New Treatment for Therapy Resistant Hypertension - A Multicenter Randomized Controlled Trial Completed NCT01850901 Phase 3
14 Effects of Losartan vs Atenolol on Aortic Stiffness and Diastolic Function in Adults With Marfan Syndrome Completed NCT00723801 Phase 3 Atenolol;Losartan
15 HALT Progression of Polycystic Kidney Disease Study B Completed NCT01885559 Phase 3 Lisinopril;Telmisartan;Placebo
16 HALT Progression of Polycystic Kidney Disease Study A Completed NCT00283686 Phase 3 Lisinopril;Telmisartan;Placebo
17 Treatment of Masked Hypertension Completed NCT02142881 Phase 3
18 A Randomized Prospective Trial Comparing Different Regimens of Polyethylene Glycol-based Lavage and Sodium Picosulphate With Magnesium Citrate in the Preparation of Patients for Colonoscopy Completed NCT01778192 Phase 3 Polyethylene glycol;Polyethylene glycol;Sodium picosulphate with magnesium citrate;Sodium picosulphate with magnesium citrate
19 Bevacizumab Pretreatment and Long Acting Gas Infusion on the Vitreous Clear-up After Diabetic Vitrectomy Completed NCT00656435 Phase 3 Bevacizumab
20 Aquanet Bowel Cleansing Device Versus Oral Sodium Picosulfate for Pre-endoscopy Bowel Preparation: Propensity Score Analysis for Interventional Effectiveness Evaluation Completed NCT03074448 Phase 3 Sodium Picosulfate
21 Treatment of Hypertension Completed NCT00000484 Phase 3 chlorothiazide;Rauwolfia alkaloids
22 A Pivotal, Multicenter, Blinded, Sham Procedure-Controlled Trial of Renal Denervation by the Peregrine System™ Kit, in Subjects With Hypertension Recruiting NCT02910414 Phase 3 Dehydrated alcohol
23 Renal Denervation Using the OneShot Ablation System Terminated NCT01844037 Phase 2, Phase 3
24 Renal Denervation in Treatment Resistant Hypertension, a Double-blind Randomized Controlled Trial Terminated NCT01762488 Phase 3
25 Renal Denervation - Hope for Patients With Refractory Hypertension? Terminated NCT01560312 Phase 3
26 Evaluation of the Benefit/Risk Ratio of a Reduction of Tacrolimus Dose in Association With Mycophenolate Mofetil on the Prevention of Complications in Adult Liver Transplantation Terminated NCT00151632 Phase 3 Mycophenolate mofetil;Tacrolimus
27 Rapid Renal Sympathetic Denervation for Resistant Hypertension Using the OneShot Renal Denervation System II Withdrawn NCT01939392 Phase 2, Phase 3
28 High Frequency Guided Renal Artery Denervation for Improving Outcome of Renal Ablation Procedure Unknown status NCT02608632 Phase 2
29 Renal Denervation in Patients With Uncontrolled Hypertension in Chinese Unknown status NCT01390831 Phase 1, Phase 2
30 Renal Protection Using Sympathetic Denervation in Patients With Chronic Kidney Disease (Kidney Protection Study - KPS Study) Unknown status NCT02002585 Phase 2
31 Rosuvastatin Use in Order to Induce Preeclampsia Resolution in Severe Preeclampsia Cases up to 48 Hours Following Delivery Unknown status NCT02314286 Phase 1, Phase 2 Rosuvastatin;Placebo
32 The Highly Sensitized Patients: Effects of Mycophenolate Mofetil (MMF) On Anti-Human Leukocyte Antigen (HLA) Antibody Levels In Patients Awaiting Cadaveric Renal Transplant Completed NCT00446459 Phase 2 mycophenolate mofetil (CellCept)
33 The Highly Sensitized Patients: Effects of Rituximab and Mycophenolate Mofetil (MMF) On Anti-Human Leukocyte Antigen (HLA) Antibody Levels In Patients Awaiting Cadaveric Renal Transplant. Completed NCT00446251 Phase 2 Rituximab;Mycophenolate mofetil (MMF)
34 A Phase 2, Multicenter, Blinded, Sham Procedure-Controlled Trial of Renal Denervation by the Peregrine System Kit, in Subjects With Hypertension, in the Absence of Antihypertensive Medications Recruiting NCT03503773 Phase 2 Alcohol
35 Comparing the Effects of an Immunosuppressant (Mycophenolate Mofetil or MMF) on the Urinary Sodium Excretion Response to Mental Stress in a Crossover Design (MMF) Recruiting NCT02432339 Phase 1, Phase 2 mycophenolate mofetil (MMF);Placebo
36 Effect of Renal Sympathetic Denervation on Resistant Hypertension and Cardiovascular Hemodynamic in Comparison to Intensive Medical Therapy Utilizing Impedance Cardiography Active, not recruiting NCT01673516 Phase 2
37 A Multi-center, Randomized, Double-blind, Parallel-group Dose-finding Study to Assess the Effect of 3 Doses of LIK066 Compared to Placebo or Empagliflozin in Type 2 Diabetes Mellitus Patients With Heart Failure Terminated NCT03152552 Phase 2 LIK066;Placebo;Empagliflozin
38 Feasibility Study of Perivascular Computer Tomography-guided Ethanol Sympatholysis for the Treatment of Therapy-resistant Arterial Hypertension Terminated NCT02653222 Phase 2
39 A Prospective, Multi-center, Non-Randomized, Feasibility Study of Catheter Based Renal Denervation to Treat Resistant Hypertension (RENABLATE-II - 157) Completed NCT02095691 Phase 1
40 A Prospective, Multi‐Center, Non‐Randomized Feasibility Study of Catheter‐Based Renal Denervation to Treat Resistant Hypertension (RENABLATE- EC12-02) Completed NCT01756300 Phase 1
41 Renal Denervation in Patients With Refractory Hypertension Completed NCT00483808 Phase 1
42 Safety and Pharmacokinetics of Lisinopril in Pediatric Kidney Transplant Recipients Completed NCT01491919 Phase 1 Lisinopril
43 Phase 1 Study of Oral L-citrulline on ADMA/L-arginine and Endothelial-dependent Vascular Function in Pregnancy. Completed NCT00743210 Phase 1 L-citrulline;Placebo
44 Nurse's Role in the Management of Hyperprolactinemia: A Prospective Randomized Controlled Trial Recruiting NCT04262024 Phase 1 Cabergoline 0.5Mg orally daily for 1 month plus health education by a nurse;Cabergoline 0.5Mg orally daily for 1 month without health education by a nurse
45 Effects of Renal Sympathetic Denervation on the Cardiac and Renal Functions in Patients With Drug-resistant Hypertension Through MRI Evaluation Unknown status NCT02164435
46 Renal Sympathetic Denervation and Insulin Sensitivity (RENSYMPIS Study) Unknown status NCT01785732
47 Wave IV Study: Phase II Randomized Sham Controlled Study of Renal Denervation for Subjects With Uncontrolled Hypertension Unknown status NCT02029885
48 Wave VI Feasibility Study: Phase II Randomized Sham Controlled Study of Renal Denervation for Untreated Stage I and II Hypertension Unknown status NCT02480517
49 A Prospective, Post-marketing, Single-arm, Open Label, Multi-center Clinical Study to Evaluate the Safety and Efficacy of the ReDy™ Renal Denervation System in the Treatment of Patients With Uncontrolled Hypertension Unknown status NCT02690909
50 Transcatheter Renal Denervation in Heart Failure With Normal Left Ventricular Ejection Fraction - a Safety and Efficacy Study of Irrigated Radiofrequency Catheter Unknown status NCT02115230

Search NIH Clinical Center for Renal Hypertension

Cochrane evidence based reviews: hypertension, renal

Genetic Tests for Renal Hypertension

Anatomical Context for Renal Hypertension

MalaCards organs/tissues related to Renal Hypertension:

40
Kidney, Heart, Testes, Liver, Endothelial, Brain, Skin

Publications for Renal Hypertension

Articles related to Renal Hypertension:

(show top 50) (show all 3200)
# Title Authors PMID Year
1
[Management of renal atrophy in hypertensive patients: experience in Lille]. 54 61
19854024 2010
2
Role of endothelin-1 in exposure to high altitude: Acute Mountain Sickness and Endothelin-1 (ACME-1) study. 61 54
16982943 2006
3
Aspirin use in older patients with heart failure and coronary artery disease: national prescription patterns and relationship with outcomes. 61 54
16168275 2005
4
Association study of calcitonin-receptor-like receptor gene in essential hypertension. 61 54
15797661 2005
5
The clinical use of angiotensin-converting enzyme inhibitors. 61 54
15586352 2004
6
Angiotensin AT-1 receptor antagonism: complementary or alternative to ACE inhibition in cardiovascular and renal disease? 54 61
12437489 2002
7
Methods for assessing endothelin ETA-receptor antagonists in preclinical studies. 54 61
12224443 2002
8
Endothelin and heart failure. 54 61
11447308 2001
9
Blacks with hypertension, renal insufficiency, and baseline proteinuria benefit more from ACE inhibition than from calcium channel blockade. 61 54
11675775 2001
10
Development of ideas on renovascular hypertension. 61 54
11022890 2000
11
[The protection of renal function in the ACEI treatment of renal hypertension]. 61 54
12206011 2000
12
Specific direct radioimmunoassay of angiotensin II (AT II) in human plasma and the effect of angiotensin converting enzyme (ACE) inhibitor. 54 61
10604545 1999
13
[Adrenomedullin]. 54 61
10352550 1999
14
[Study on the relationship between plasma endothelin nitric oxide concentration and renal hypertension and renal function]. 54 61
12080656 1999
15
Anti-ischaemic effects of ACE inhibitors: review of current clinical evidence and ongoing clinical trials. 54 61
9796839 1998
16
Endothelin as a regulator of cardiovascular function in health and disease. 54 61
9794709 1998
17
Adrenomedullin: a new modulator of vascular tone. 54 61
8951571 1996
18
Adrenomedullin: a new hypotensive peptide. 54 61
9120666 1996
19
[Arterial hypertension in patients on chronic hemodialysis]. 61 54
9102857 1996
20
Therapeutic advantages of angiotensin converting enzyme inhibitors in chronic renal disease. 54 61
8743512 1996
21
[A protein-restricted diet combined with ACE inhibitors does not improve insulin sensitivity in renal hypertension]. 61 54
8686202 1996
22
Role of bradykinin in the antihypertensive and cardioprotective actions of converting enzyme inhibitors. 61 54
8846416 1995
23
Relation between renin and prorenin in plasma from hypertensive patients and normal people: evidence for different renin:prorenin ratios. 61 54
7473533 1995
24
[The use of angiotensin-converting enzyme inhibitors in chronic diffuse kidney diseases]. 54 61
7638769 1995
25
Dopamine beta-hydroxylase immunoreactivity in human cerebrospinal fluid: properties, relationship to central noradrenergic neuronal activity and variation in Parkinson's disease and congenital dopamine beta-hydroxylase deficiency. 61 54
8143425 1994
26
Renal vein renin analysis: limitations of its use in predicting benefit from percutaneous angioplasty. 61 54
8485747 1993
27
Urinary kallikrein excretion is low in malignant essential hypertension. 61 54
1325521 1992
28
Angiotensin converting enzyme inhibitors in cardiovascular and renal disease in Africans: a review. 54 61
1908620 1991
29
Antihypertensive effects of allicin on spontaneously hypertensive rats via vasorelaxation and hydrogen sulfide mechanisms. 61
32480217 2020
30
No news is good news? Three-year postdischarge mortality of octogenarian and nonagenarian patients following emergency general surgery. 61
32569106 2020
31
Rapidly progressive glomerulonephritis and acute kidney injury associated with cocaine use - Case report. 61
32573647 2020
32
Cardiovascular Health in American Indians and Alaska Natives: A Scientific Statement From the American Heart Association. 61
32460555 2020
33
Disparity in access to bariatric surgery among African-American men. 61
31385077 2020
34
Renal sympathetic nerve activity regulates cardiovascular energy expenditure in rats fed high salt. 61
31932643 2020
35
Diastolic Dysfunction in Patients With Human Immunodeficiency Virus Receiving Antiretroviral Therapy: Results From the CHART Study. 61
31682908 2020
36
Temporal hemodynamic changes in a female mouse model of systemic lupus erythematosus. 61
32150445 2020
37
Aromatase inhibitors attenuate the effect of alendronate in women with breast cancer. 61
32405760 2020
38
Intracranial vascular pathology in two further patients with Floating-Harbor syndrome: Proposals for cerebrovascular disease risk management. 61
31605816 2020
39
Increased Mortality in Asians With Systemic Sclerosis in Northern California. 61
32198914 2020
40
E/e' in relation to outcomes in ST-elevation myocardial infarction. 61
32242982 2020
41
Correlations Between Interleukin-11 Expression and Hypertensive Kidney Injury in a Rat Model of Renovascular Hypertension. 61
31840157 2020
42
Fragmented QRS in prediction of ischemic heart disease diagnosed by stress cardiovascular magnetic resonance imaging. 61
32320122 2020
43
α2A-Adrenoceptors Modulate Renal Sympathetic Neurotransmission and Protect against Hypertensive Kidney Disease. 61
32086277 2020
44
Does race impact functional outcomes in patients undergoing robotic partial nephrectomy? 61
32420201 2020
45
A Positive Cocaine Urine Toxicology Test and the Effect on Intraoperative Hemodynamics Under General Anesthesia. 61
32304462 2020
46
Overall survival and factors predicting long-term outcome after thoracic aortic endovascular repair. 61
32126933 2020
47
No News is Good News? Three-year Post-Discharge Mortality of Octogenarian and Nonagenarian Patients Following Emergency General Surgery. 61
32251266 2020
48
Afferent innervation of the ischemic kidney contributes to renal dysfunction in renovascular hypertensive rats. 61
31925527 2020
49
Epidemiology, Comorbidities, and Outcomes of Posterior Reversible Encephalopathy Syndrome in Children in the United States. 61
31481327 2020
50
Hypertensive Disorders of Pregnancy and Future Cardiovascular Health. 61
32351977 2020

Variations for Renal Hypertension

Expression for Renal Hypertension

Search GEO for disease gene expression data for Renal Hypertension.

Pathways for Renal Hypertension

Pathways related to Renal Hypertension according to GeneCards Suite gene sharing:

(show all 11)
# Super pathways Score Top Affiliating Genes
1 12.62 KNG1 EPO EDN1 AGTR1 AGT
2
Show member pathways
12.59 NOS3 EPO EDN1 AGTR1 AGT
3
Show member pathways
12.27 NPPB NOS3 KNG1 AGTR1 AGT
4
Show member pathways
11.96 NPPB NOS3 MYH9 EDN1 AGTR1 AGT
5 11.62 NOS3 EDN1 AGTR1 AGT
6 11.47 EPO EDN1 ADM
7 11.39 REN EDN1 AGTR1 AGT ACE
8 11.37 NOS3 EPO EDN1
9 11.21 MIR200B MIR200A MIR141
10
Show member pathways
11 REN NOS3 KNG1 AGTR1 AGT ACE
11 10.79 GPR182 DBH ADM

GO Terms for Renal Hypertension

Cellular components related to Renal Hypertension according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell GO:0005623 9.76 SLC12A3 NOS3 MYH9 KNG1 EDN1 AGTR1
2 extracellular region GO:0005576 9.73 REN NPPB KNG1 KLKB1 EPO EDN1
3 blood microparticle GO:0072562 9.56 KNG1 APOL1 ALB AGT
4 extracellular space GO:0005615 9.44 REN NPPB MIR141 KNG1 KLKB1 EPO

Biological processes related to Renal Hypertension according to GeneCards Suite gene sharing:

(show all 27)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 10.02 MIR200B MIR141 EPO EDN1 AGT ADM
2 response to lipopolysaccharide GO:0032496 9.85 REN NOS3 EPO EDN1 ADM
3 kidney development GO:0001822 9.81 REN AGTR1 AGT ACE
4 positive regulation of cytosolic calcium ion concentration GO:0007204 9.8 KNG1 EDN1 AGTR1 AGT ADM
5 vasodilation GO:0042311 9.65 NOS3 KNG1 AGT
6 amyloid-beta metabolic process GO:0050435 9.63 REN ACE
7 positive regulation of urine volume GO:0035810 9.63 NPPB EDN1
8 low-density lipoprotein particle remodeling GO:0034374 9.62 AGTR1 AGT
9 negative regulation of blood coagulation GO:0030195 9.62 KNG1 EDN1
10 blood vessel remodeling GO:0001974 9.62 NOS3 DBH AGT ACE
11 angiotensin maturation GO:0002003 9.61 REN ACE
12 response to dexamethasone GO:0071548 9.61 EPO EDN1
13 positive regulation of renal sodium excretion GO:0035815 9.61 NPPB EDN1 AGT
14 artery smooth muscle contraction GO:0014824 9.6 EDN1 AGT
15 positive regulation of cholesterol esterification GO:0010873 9.59 AGTR1 AGT
16 body fluid secretion GO:0007589 9.58 NPPB EDN1
17 positive regulation of NAD(P)H oxidase activity GO:0033864 9.58 AGTR1 AGT
18 regulation of systemic arterial blood pressure by endothelin GO:0003100 9.57 NOS3 EDN1
19 regulation of renal sodium excretion GO:0035813 9.56 AGTR1 AGT
20 regulation of blood vessel diameter by renin-angiotensin GO:0002034 9.54 AGTR1 AGT
21 regulation of systemic arterial blood pressure by renin-angiotensin GO:0003081 9.54 AGTR1 AGT ACE
22 regulation of blood volume by renin-angiotensin GO:0002016 9.52 REN AGT
23 regulation of renal output by angiotensin GO:0002019 9.49 AGT ACE
24 regulation of vasoconstriction GO:0019229 9.46 EDN1 AGTR1 AGT ACE
25 renin-angiotensin regulation of aldosterone production GO:0002018 9.43 REN AGTR1 AGT
26 regulation of blood vessel diameter GO:0097746 9.26 NPPB NOS3 AGTR1 ACE
27 regulation of blood pressure GO:0008217 9.1 REN NPPB NOS3 EDN1 AGT ACE

Molecular functions related to Renal Hypertension according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 signaling receptor binding GO:0005102 9.55 REN NPPB KNG1 EDN1 ADM
2 hormone activity GO:0005179 9.02 NPPB EPO EDN1 AGT ADM
3 bradykinin receptor binding GO:0031711 8.96 AGTR1 ACE

Sources for Renal Hypertension

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....